After buying Apellis for $5.6B, Biogen is cutting most of its pipeline worknews2026-06-26T00:50:05+00:00June 26th, 2026|Endpoints News|
Merck KGaA makes largest deal in a decade in $11.3B buy for Bio-Technenews2026-06-25T15:23:10+00:00June 25th, 2026|Endpoints News|
How GSK’s new CEO lined up a major buyout to start his time at the topnews2026-06-25T00:26:42+00:00June 25th, 2026|Endpoints News|
Remix does reverse merger with Passage Bio for mRNA degradernews2026-06-24T20:05:37+00:00June 24th, 2026|Endpoints News|
Novartis taps Antares in small molecule discovery pact with $105M upfrontnews2026-06-24T14:56:26+00:00June 24th, 2026|Endpoints News|
Endpoints H1 2026 CEO survey: Fallout from MFN and suggestions for the FDAnews2026-06-24T14:00:47+00:00June 24th, 2026|Endpoints News|
Lilly offers up to $1.9B in new drug discovery deal with Abbiskonews2026-06-24T10:14:04+00:00June 24th, 2026|Endpoints News|
BIO board met with US officials on China, CEO saysnews2026-06-23T18:18:50+00:00June 23rd, 2026|Endpoints News|
Sangamo’s three-decade run comes to a close as Lilly and Astellas eye assetsnews2026-06-23T15:57:02+00:00June 23rd, 2026|Endpoints News|
AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidatesnews2026-06-22T11:03:23+00:00June 22nd, 2026|Endpoints News|
